Table 1.
BRCA1 Deficient-Like ( BD-L ) distribution in a breast cancer cell line panel
| Cell line | ER | PR | HER2 | BRCA1 | BD-L metagene value |
|---|---|---|---|---|---|
| HCC1143 |
- |
- |
- |
NA |
207.2555 |
| MDAMB415 |
+ |
- |
- |
wt/- |
208.6937 |
| HCC1937 |
- |
- |
- |
m/- |
226.181 |
| BT20 |
- |
- |
- |
wt/- |
227.6686 |
| MDAMB468 |
- |
- |
- |
wt/- |
260.2652 |
| BT474 |
+ |
+ |
+ |
wt/- |
261.2111 |
| HCC1428 |
+ |
+ |
- |
NA |
265.375 |
| MDAMB134VI |
+ |
- |
- |
wt/wt |
267.9736 |
| SKBR3 |
- |
- |
+ |
wt/- |
277.6819 |
| MCF10A |
- |
- |
- |
NA |
285.3522 |
| HCC1954 |
- |
- |
+ |
NA |
300.0448 |
| HCC1500 | - | - | - | NA | 300.3202 |
Breast cancer cell lines selected for pharmacological inhibition evaluation. BD-L metagene values for the cell lines, as calculated from the Neve et al. [21] data set, are listed by increasing value. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein expression status are indicated. If known, the BRCA1 mutational status is noted (NA: not available).